HELIOS-A 18-Month Phase 3 Results for AMVUTTRA™ (vutrisiran) Published in Amyloid

HELIOS-A 18-Month Phase 3 Results for AMVUTTRA™ (vutrisiran) Published in Amyloid

Eighteen-month efficacy and safety results from the HELIOS-A Phase 3 study of AMVUTTRA™ (vutrisiran), an RNAi therapeutic recently approved in the U.S. for adults with the polyneuropathy of hereditary ATTR (hATTR) amyloidosis, were published in Amyloid.

Read the paper in Amyloid



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.